chen, chenyan – page 10 – eisai china lnc.-pg电子app

tokyo and stamford, conn. – february 4, 2019 – eisai co., ltd. (ceo: haruo naito, “eisai”) and purdue pharma l.p. (president and ceo: craig landau, md, “purdue pharma”) today announced six-month results from sunrise 2, a long-term phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder. data were presented at the sleep research society’s advances in sleep and circadian science conference, taking place in clearwater beach, florida, feb. 1-4, 2019.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has been listed in the 2019 global 100 most sustainable corporations in the world (global 100), a global ranking by canada-based media and investment advisory company, corporate knights, inc. this marks eisai’s fourth inclusion on the list. ranked 73rd, eisai was the highest ranking japanese company among the eight japanese companies listed in the global 100.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced that its in-house discovered and developed antiepileptic drug (aed) perampanel (generic name, product name: fycompa®), for which  a new drug application (nda) was submitted for review as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older in china in october 2018, has been designated for priority review by the national medical products administration (nmpa) due to perampanel’s significant clinical benefit compared to existing treatments.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the latest data on its antiepileptic drug (aed) perampanel (product name: fycompa®) will be presented at the 72nd american epilepsy society annual meeting (aes 2018) to be held from november 30 to december 4, 2018 in new orleans in the united states.

november 7, 2018, eisai china inc. (eci) held the inauguration ceremony for its new suzhou plant located at no. 168 xingpu road within the suzhou industrial park. mr. kazuyuki katayama (consulate-general of japan in shanghai), mr. yue wang (commissioner of jiangsu food and drug administration), mr. qingwen wu (standing committee of suzhou municipality and secretary general of the party committee of suzhou industrial park administrative committee (sipac)), ms.  yanyan sun (deputy director of sipac), mr. jianmin chen (director-general of suzhou food and drug administration), dr. haruo naito (ceo of eisai co., ltd.), mr. yasushi okada (representative corporate officer of ecl, industry affairs and china business), ms. yanhui feng (vice president of ecl, president of eisai china), mr. norio kaneko (chairman of eisai china) and people with close attention to the development of eisai china attended the ceremony.